BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
90.17
+11.84 (15.12%)
At close: Jul 9, 2026, 4:00 PM EDT
90.24
+0.07 (0.08%)
After-hours: Jul 9, 2026, 6:09 PM EDT
BridgeBio Pharma Employees
As of December 31, 2025, BridgeBio Pharma had 839 total employees, including 834 full-time and 5 part-time employees. The number of employees increased by 109 or 14.93% compared to the previous year.
Employees
839
Change (1Y)
109
Growth (1Y)
14.93%
Revenue / Employee
$691,249
Profits / Employee
-$860,014
Market Cap
17.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 839 | 109 | 14.93% | 834 | 5 |
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | 578 | 182 | 45.96% | 576 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
BBIO News
- 8 hours ago - BridgeBio rises 17.0% - TheFly
- 7 days ago - Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM - GlobeNewsWire
- 8 days ago - BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - GlobeNewsWire
- 10 days ago - BridgeBio announces PROPEL 3 trial met primary endpoint - TheFly
- 11 days ago - BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - GlobeNewsWire
- 11 days ago - BridgeBio Pharma Slides: Conference presentation - Filings
- 16 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - BridgeBio Pharma Transcript: AGM 2026 - Transcripts